long intergenic non-protein coding RNA 1667Genealiases: []
Q-omics provides the consensus-scored LINC01667 profile across patient tissues and cancer cell-line models. LINC01667 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LINC01667 is differentially expressed in 4, with the highest sampling consensus in LIHC. Additionally, LINC01667 RNA expression shows 6,260 significant pathway-activity associations, with the highest sampling consensus in LIHC. Together, these results highlight KIRP, and LIHC as cancer lineages where LINC01667 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01667 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01667 survival associations across molecular data types. LINC01667 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01667 RNA expression–survival associations across cancer types. High LINC01667 expression shows unfavorable associations in KIRP, BRCA, LIHC, HNSC, UCEC and COAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LINC01667 RNA expression.
This table summarizes LINC01667 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01667. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01667 shows lower tumor expression in BRCA and LUSC and higher tumor expression in LIHC, UCEC and LUSC. The LIHC box plot shows higher LINC01667 RNA expression in tumor versus normal tissue (log2 FC = +0.465, t-test p = .001).
This table shows molecular features associated with LINC01667 in patient tissues and cancer cell lines. In patient samples, LINC01667 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
